Roberts and Der (2007) used an EGFR-Ras-Raf-MEK-ERK pathway to explain that 10% of NSCLC arise from EGFR mutations and that 30% of NSCLC arise from mutations in Ras [30]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.